This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Opinion: Discussing the standard of care and the use of Zeposia (ozanimod) in treating Ulcerative Colitis

Ticker(s): BMY

Who's the expert?

Institution: NYU Langone Long Island 

  • Medical Director for the Inflammatory Bowel Diseases (IBD) Program at NYU Langone Long Island
  • Practice encompasses all facets of general gastroenterology including gastroesophageal reflux disease (GERD), peptic ulcer disease, chronic constipation, ulcerative colitis and irritable bowel syndrome (IBS), with additional expertise in inflammatory bowel diseases
  • Co-authored several studies in inflammatory bowel disease 
  • Manages 150 patients with ulcerative colitis and prescribes Zeposia to 5 patients

Interview Goal
The goal if this interview is to discuss the standard of care and the use of Zeposia (ozanimod) in treating UC

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.